Skip to headerSkip to main contentSkip to footer
Get our Free E-newslettersGet our Free E-newsletters
Kiplinger logoLink to homepage
Get our Free E-newslettersGet our Free E-newsletters
Subscribe to Kiplinger
Subscribe to Kiplinger
Save up to 76%
Subscribe
Subscribe to Kiplinger
  • Store
  • Home
  • Investing
  • Retirement
  • Taxes
  • Personal Finance
  • Your Business
  • Wealth Creation
    • Podcasts
    • Economic Outlooks
    • Tools
    • Kiplinger's Personal Finance Magazine
    • The Kiplinger Letter
    • The Kiplinger Tax Letter
    • Kiplinger's Investing for Income
    • Kiplinger's Retirement Report
    • Store
    • Manage My E-Newsletters
    • My Subscriptions
Skip advert
  • Home
  • investing
investing

3 Reasons to Buy Pfizer Stock for Retirement

Blue-chip dividend-paying stocks should be part of any retirement portfolio, and one of the best of the bunch these days is drugmaker Pfizer (symbol PFE).

by: Dan Burrows
January 4, 2017

Courtesy of Pfizer Inc.

Skip advert

Blue-chip dividend-paying stocks should be part of any retirement portfolio, and one of the best of the bunch these days is drugmaker Pfizer (symbol PFE). Here are three reasons we like the stock for retirees.

Figures are as of Dec. 29 unless otherwise indicated.

Skip advert
Skip advert
Skip advert

1 of 3

A Big, Steady Business

iStock

Skip advert

With sales estimated at more than $51 billion in 2016, Pfizer ranks as one of the world’s largest pharmaceutical companies. The firm muddled through a few slow years after its patent for the cholesterol drug Lipitor expired in 2011, but it’s past that now. Investments in research and development, along with acquisitions, have resulted in several hit drugs on the market, including Ibrance, to treat breast cancer, blood thinner Eliquis and Xeljanz, a treatment for rheumatoid arthritis. Pfizer is now working on 94 drugs, including 41 in late-stage development to treat various cancers, diabetes and other ailments.

Pfizer is also expanding into the fast-growing market for generic versions of biotech drugs. The firm recently launched a “biosimilar” knockoff of Remicade, Johnson & Johnson’s (symbol JNJ) best-selling arthritis treatment with more than $5 billion in annual sales. Pfizer aims to sell its biosimilar version at a 15% discount -- savings that may be passed on to patients, making the deal hard to pass up.

Finally, Pfizer is using its massive financial muscle to make deals that are fueling growth. Its 2015 merger with Hospira, the company behind the Remicade biosimilar, has added more than $1 billion in quarterly sales to Pfizer’s revenues. The company also recently completed a $14 billion deal to buy prostate-cancer drugmaker Medivation.

 

  • 8 Stocks to Benefit from Rising Interest Rates
Skip advert
Skip advert
Skip advert

2 of 3

Attractively Priced “Defensive” Stock

iStock

Skip advert

Whether the economy is expanding or contracting, demand for medications remains steady. That makes Pfizer one of the stronger defensive stocks you can buy. The shares fell by 16% in 2008, a year in which Standard & Poor’s 500-stock index declined by 37% (including dividends). Pfizer has trailed the S&P 500 over the past five years. But the stock has produced annualized returns of 11.6% (including dividends) in that stretch--a respectable showing for such a large company.

The shares look relatively inexpensive, too. Trading at about 14 times estimated earnings for 2017, the stock looks much cheaper than the S&P 500, which has a price-earning ratio of 17. Pfizer does trade at a higher trailing P/E ratio than its average over the past five years, according to Morningstar. But the past five years were a transition period between slowing sales of off-patent drugs and the emergence of new hits. Pfizer’s prospects look brighter today, with a stronger roster of drugs in development and several acquisitions that should help produce solid earnings for years.

 

  • 3 Reasons to Own Apple Stock in Retirement
Skip advert
Skip advert
Skip advert

3 of 3

Dependable Dividends

iStock

Skip advert

Many retirees need a reliable income stream, and Pfizer stacks up well in that department. The stock currently yields 3.6%—more than you can earn from a 10-year Treasury bond (2.5%) or the S&P 500 (2.1%).

Investors can also take comfort in the fact that Pfizer has paid uninterrupted dividends every year since 1980. The company has raised its payout every year since 2010. And Pfizer should have no trouble making regular payments. Analysts estimate that the company will distribute more than $7 billion in dividends in 2017, easily covered by net income of $15.9 billion.

 

  • 5 Telecom Stocks Paying Big Dividends
Skip advert
Skip advert
Skip advert
  • dividend stocks
  • bonds
  • investing
  • Pfizer (PFE)
Share via EmailShare on FacebookShare on TwitterShare on LinkedIn
Skip advert
Skip advert
Skip advert
Skip advert

Recommended

Is the Stock Market Closed for the Fourth of July in 2022?
Markets

Is the Stock Market Closed for the Fourth of July in 2022?

Independence Day falls on a Monday in 2022, so the bond and stock markets will enjoy a long holiday weekend. Here's a look at the markets' holiday hou…
July 1, 2022
Top Bear Market Tips from 10 Financial Advisers
investing

Top Bear Market Tips from 10 Financial Advisers

When a bull market turns into a bear market, it can be hard to know what to do. Take comfort in the guidance of 10 financial professionals.
June 30, 2022
5 Best Dow Dividend Stocks to Buy Now
blue chip stocks

5 Best Dow Dividend Stocks to Buy Now

This mini-portfolio of blue-chip dividend payers is well-positioned to both generate income and hold up to headwinds for the rest of 2022.
June 27, 2022
Move Over ETFs: Direct Indexing Is an Investment Strategy Worth Paying Attention to
investing

Move Over ETFs: Direct Indexing Is an Investment Strategy Worth Paying Attention to

More flexibility, more control, the potential for higher returns and tax-reducing strategies: With pros like that, could direct indexing be right for …
June 25, 2022

Most Popular

5 Best Dow Dividend Stocks to Buy Now
blue chip stocks

5 Best Dow Dividend Stocks to Buy Now

This mini-portfolio of blue-chip dividend payers is well-positioned to both generate income and hold up to headwinds for the rest of 2022.
June 27, 2022
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
Top Bear Market Tips from 10 Financial Advisers
investing

Top Bear Market Tips from 10 Financial Advisers

When a bull market turns into a bear market, it can be hard to know what to do. Take comfort in the guidance of 10 financial professionals.
June 30, 2022
  • Customer Service
  • About Us
  • Advertise With Us (PDF)
  • Privacy Policy
  • Cookie Policy
  • Kiplinger Careers
  • Accessibility
  • Privacy Preferences

Subscribe to Kiplinger's Personal Finance

Be a smarter, better informed investor.
Save up to 76%Subscribe to Kiplinger's Personal Finance
Do Not Sell My Information

Kiplinger is part of Future plc, an international media group and leading digital publisher. Visit our corporate site www.futureplc.com
© Future US LLC, 10th floor, 1100 13th Street NW, Washington, DC 20005. All rights reserved.

Follow us on InstagramFollow us on FacebookFollow us on TwitterConnect on LinkedInConnect on YouTube